Kajimoto Hidemi, Nakazawa Makoto, Murasaki Kagari, Hagiwara Nobuhisa, Nakanishi Toshio
Department of Pediatric Cardiology, Heart Institute of Japan, Tokyo Women's Medical University, Tokyo, Japan.
Circ J. 2009 Sep;73(9):1705-10. doi: 10.1253/circj.cj-08-1087. Epub 2009 Jul 28.
Thromboembolic events account for significant morbidity and mortality after the Fontan procedure, but the underlying mechanisms remain unclear. P-selectin on platelets indicates platelet activation. Thrombomodulin (TM), a receptor for thrombin and a major anticoagulant proteoglycan on the endothelial membrane, reflects the anticoagulant activity of the endothelium. The present study investigated the hypothesis that the balance between platelet activation and endothelial biological function is impaired in Fontan patients.
Platelet P-selectin as a marker of platelet activation, plasma TM levels and protein C activity, as markers of anticoagulant activity of the endothelium, and thrombin-antithrombin complex III (TAT) were examined in 43 Fontan patients. P-selectin levels on platelets (4.5 +/-1.4 vs 3.4 +/-0.4 mean fluorescence intensity, P<0.001) and TAT levels (80.2 +/-322.6 vs 1.9 +/-0.9 ng/ml, P<0.05) were significantly higher in Fontan patients than in control subjects. On the other hand, plasma TM levels (1.5 +/-0.8 vs 2.2 +/-0.3 FU/ml, P<0.01) and protein C activity (71 +/-35 vs 118 +/-25%, P<0.001) were significantly lower in Fontan patients compared with controls. These abnormalities were not seen in patients after other surgical procedures for congenital heart disease.
Platelet activation is enhanced and endothelial function is impaired in patients after the Fontan procedure, which may partly explain the thromboembolic complications in Fontan patients.
血栓栓塞事件在Fontan手术后导致显著的发病率和死亡率,但其潜在机制仍不清楚。血小板上的P-选择素表明血小板活化。血栓调节蛋白(TM)是凝血酶的受体,也是内皮细胞膜上的主要抗凝蛋白聚糖,反映内皮的抗凝活性。本研究探讨了Fontan患者血小板活化与内皮生物学功能之间的平衡受损这一假说。
对43例Fontan患者检测了作为血小板活化标志物的血小板P-选择素、作为内皮抗凝活性标志物的血浆TM水平和蛋白C活性以及凝血酶-抗凝血酶复合物III(TAT)。Fontan患者的血小板P-选择素水平(平均荧光强度4.5±1.4 vs 3.4±0.4,P<0.001)和TAT水平(80.2±322.6 vs 1.9±0.9 ng/ml,P<0.05)显著高于对照组。另一方面,Fontan患者的血浆TM水平(1.5±0.8 vs 2.2±0.3 FU/ml,P<0.01)和蛋白C活性(71±35 vs 118±25%,P<0.001)显著低于对照组。这些异常在接受其他先天性心脏病手术的患者中未出现。
Fontan手术后患者的血小板活化增强且内皮功能受损,这可能部分解释了Fontan患者的血栓栓塞并发症。